Track topics on Twitter Track topics that are important to you
Cambridge-based company, Evonetix, has completed a series A financing round, raising $12.3 million to be used in the advancement of its novel gene synthesis platform.
Cambridge, UK-based Evonetix has raised £9 million to help fuel the advance of its technology designed to enable scalable and high-fidelity gene synthesis.
Evonetix has closed a Series A fundraising round to support the development of its gene synthesis platform, an important tool in the emerging synbio field. Evonetix, based in Cambridge, UK, is develop...
Series A round co-led by Silicon Valley investor DCVC and London-based Draper Esprit. EVONETIX LTD, the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity g...
Series A round co-led by Silicon Valley investor DCVC and London-based Draper Esprit EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative...
Series A round co-led by Silicon Valley investor DCVC and London-based Draper Esprit CAMBRIDGE, UK, 30th January 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company...
We have published hundreds of Evonetix Ltd news stories on BioPortfolio along with dozens of Evonetix Ltd Clinical Trials and PubMed Articles about Evonetix Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evonetix Ltd Companies in our database. You can also find out about relevant Evonetix Ltd Drugs and Medications on this site too.